Skip to main content
Shop Plans Learn more about our coverage options including health, Medicare, dental and vision options for you, your family or your employees. Get Started Individual & Family Medicare Employer Vision Dental International Travel Find Care FAQ Blog Members Stay on top of your health care with helpful member resources. Members Home Medicare Health Dental Vision Find Care Member Knowledge Center Member Forms Medicare Forms Library Make a Payment Federal Employees Student Blue Healthy Blue Providers Access tools, policies and the latest information to help you care for our members. Providers Home Network Participation Networks & Programs Claims, Appeals & Inquiries Prior Authorization Services & CPT codes Prescription Drug Search Policies, Guidelines & Codes Provider News Provider FAQ Contact Us Employers Learn about our coverage options for small and large employers, and access tools and resources for your group. Employers Home Shop Employer Plans Employer Portal Support Member Forms & Resources Find Care Blog Agents Access the tools you need: rate quotes, applications, forms, the latest industry news, marketing materials and more. Agents Home Agent Services Check Eligibility Find Care Member Forms & Resources Medicare Forms Library
Contact Us
Log In
I am ... Please select A member A provider An employer An agent
Log in to Agent Services
Log in to Employer Services Register for Employer Services I'm registered but need portal access
Username Forgot username? Continue to Log In Register for Blue Connect Need help? Learn how to log in.
Log in to Blue e Register for Blue e Log in to Dental Blue
Back
Blue Cross NC Adds New Biosimilars for Humira (adalimumab) to Commercial Formularies July 07, 2023 Pharmacy

On 7/1/2023, new biosimilars for Humira (adalimumab) will be added to Blue Cross and Blue Shield of North Carolina commercial formularies. There will be no changes in coverage of Humira products. Coverage of specific biosimilars will vary by formulary, but may include Amjevita, Cyltezo, or Hadlima. You can identify preferred products on MyPrime.com after 7/1/2023. Because there are no clinically meaningful differences between Humira and the biosimilar adalimumab products, patients are not expected to experience a change in the safety or effectiveness of their treatment if members utilize covered adalimumab biosimilars. Refer to the FDA resource (PDF) for further information.